Amanat Signs $200M Corxel De-SPAC With $300M PIPE and $200M Minimum Cash Condition
AMAN is trading near its 52-week low of $9.98 (2.4% above the low).
Summary
Amanat signed a definitive business combination with Corxel Pharmaceuticals at a $200 million implied equity value, paired with a $300 million PIPE and a $200 million minimum cash condition; closing is expected in the first half of 2027.
Key Events · M&A and Partnerships · AMAN
-
Corxel De-SPAC Signed
Amanat will domesticate to Delaware and merge with Corxel Pharmaceuticals at an implied Corxel equity value of $200,000,000, with Corxel holders receiving New Corxel common stock at an exchange ratio set on the allocation schedule.
-
$300M PIPE Committed
Subscription agreements with qualified institutional buyers and accredited investors, including existing Corxel stockholders, cover aggregate purchase commitments of $300 million of New Corxel common stock and/or pre-funded warrants.
-
$200M Minimum Cash Condition
Corxel only has to close if trust cash after redemptions, plus PIPE proceeds and up to $75,000,000 of its own cash, totals at least $200,000,000 — against a trust account of at least $76,127,312.83 as of the agreement date.
-
Termination Fees Set
Corxel pays the greater of $10,000,000 and 1% of upfront consideration (capped at $50,000,000) to take a superior offer, $10,000,000 on an adverse recommendation change, and up to $3,000,000 of costs on a regulatory block.
Analysis · AMAN · Real Estate & Construction
Amanat, a SPAC trading near its 52-week low, has finally signed a deal: Corxel Pharmaceuticals goes public at a $200 million implied equity value, backed by $300 million of committed PIPE money. The structure matters more than the headline. Corxel's side only has to close if at least $200 million of cash is available after redemptions, PIPE proceeds and up to $75 million of Corxel's own cash — so the deal is effectively underwritten by the PIPE rather than by Amanat's $76.1 million trust. That protects against a heavy redemption wave, but it also means the PIPE has to fund. Existing Amanat holders can still redeem at the pro rata trust value, and the sponsor has given up its Class B anti-dilution adjustment and locked up for six months, which removes two common overhangs. The main risk is timing: closing is targeted for the first half of 2027 and still needs the S-4 to go effective, HSR clearance, Nasdaq listing approval and both shareholder votes.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMAN was trading at $10.22 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $101.8M. The 52-week trading range was $9.98 to $10.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.